ArticleEye (London, England)2026
Functional and structural analysis in relation to age at onset of Leber hereditary optic neuropathy: a Swedish cohort.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo evaluate macular ganglion cell complex (GCC) thickness, retinal vessel tortuosity, visual function, and treatment effects in chronic Leber hereditary optic neuropathy (LHON) stratified by age at onset.
methodsThirty-one chronic LHON subjects from the Swedish LHON registry were enrolled and grouped by age at onset: <15 years, ≥15 to ≤35 years, and ≥36 years. Visual acuity (VA), visual fields, optical coherence tomography (OCT), and fundus images were assessed. Vessel tortuosity was qualitatively graded. Idebenone treatment history was obtained from the registry.
resultsFifty-nine eyes were analysed. Six eyes exhibited no to mild visual impairment, of which four belonged to individuals with age at onset <15 years. This group demonstrated significantly better VA (0.7 ± 0.8 vs 1.5 ± 0.5 and 1.3 ± 0.5 logMAR), higher visual field score (76.9 ± 25.8 vs 47.1 ± 27.7 and 29.7 ± 21.1%), and thicker average GCC (72.3 ± 30.8 vs 49.9 ± 11.6 and 48.7 ± 4.5 µm) compared with older-onset groups. Moderate to severe tortuosity was more prevalent in the youngest-onset group. Among individuals with onset ≥15 to ≤35 years, GCC thickness correlated with visual function. Overall, 68% received Idebenone and majority of them were treated within six months of onset (68%), but no significant outcome differences were observed between the treated and untreated subjects.
conclusionsLHON onset before 15 years of age is associated with better preserved retinal structure and visual function in the chronic stage.
Identifiers
42778668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.